Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease

Shinichi Sueta, Kunio Morozumi, Asami Takeda, Keiji Horike, Yasuhiro Otsuka, Hibiki Shinjo, Minako Murata, Yuki Kato, Kazunori Goto, Daijo Inaguma

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Vitamin D deficiency is common among patients with chronic kidney disease (CKD). However, the benefits of vitamin D supplementation versus vitamin D receptor activator (VDRA) administration have yet to be established. Recently, an association between activated vitamin D and cardiovascular factors was reported. To evaluate the benefits of VDRA in advanced CKD, we analyzed the association between VDRA administration and the prevalence of pulmonary congestion. Methods: This retrospective, cross-sectional analysis included patients initiated on dialysis between October 2011 and September 2013 at 17 Japanese institutions. Data from 952 participants were analyzed using a multivariate logistic regression model and a linear regression model. We also analyzed subgroup data for groups classified by selection of peritoneal dialysis or hemodialysis. Results: Of the 952 participants, 303 patients received VDRA. VDRA administration was associated with a low prevalence of pulmonary congestion in the multivariate logistic regression model (odds ratio [OR], 0.64; 95 % confidence interval [CI], 0.44–0.94; P = 0.02). There was no significant association between VDRA administration and systolic blood pressure, diastolic blood pressure, or pulse pressure. Subgroup analysis revealed a tendency that VDRA administration was associated with low prevalence of pulmonary congestion in both groups. Conclusions: In this study, VDRA administration was associated with a low prevalence of pulmonary congestion in patients initiated on dialysis. Appropriate VDRA administration may prevent pulmonary congestion.

Original languageEnglish
Pages (from-to)371-378
Number of pages8
JournalClinical and Experimental Nephrology
Volume19
Issue number3
DOIs
Publication statusPublished - 17-06-2015

Fingerprint

Calcitriol Receptors
Chronic Renal Insufficiency
Lung
Blood Pressure
Logistic Models
Vitamin D
Dialysis
Linear Models
Vitamin D Deficiency
Peritoneal Dialysis
Renal Dialysis
Cross-Sectional Studies
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Sueta, Shinichi ; Morozumi, Kunio ; Takeda, Asami ; Horike, Keiji ; Otsuka, Yasuhiro ; Shinjo, Hibiki ; Murata, Minako ; Kato, Yuki ; Goto, Kazunori ; Inaguma, Daijo. / Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease. In: Clinical and Experimental Nephrology. 2015 ; Vol. 19, No. 3. pp. 371-378.
@article{3f29d23b798142fdafd95da12a91c8b2,
title = "Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease",
abstract = "Background: Vitamin D deficiency is common among patients with chronic kidney disease (CKD). However, the benefits of vitamin D supplementation versus vitamin D receptor activator (VDRA) administration have yet to be established. Recently, an association between activated vitamin D and cardiovascular factors was reported. To evaluate the benefits of VDRA in advanced CKD, we analyzed the association between VDRA administration and the prevalence of pulmonary congestion. Methods: This retrospective, cross-sectional analysis included patients initiated on dialysis between October 2011 and September 2013 at 17 Japanese institutions. Data from 952 participants were analyzed using a multivariate logistic regression model and a linear regression model. We also analyzed subgroup data for groups classified by selection of peritoneal dialysis or hemodialysis. Results: Of the 952 participants, 303 patients received VDRA. VDRA administration was associated with a low prevalence of pulmonary congestion in the multivariate logistic regression model (odds ratio [OR], 0.64; 95 {\%} confidence interval [CI], 0.44–0.94; P = 0.02). There was no significant association between VDRA administration and systolic blood pressure, diastolic blood pressure, or pulse pressure. Subgroup analysis revealed a tendency that VDRA administration was associated with low prevalence of pulmonary congestion in both groups. Conclusions: In this study, VDRA administration was associated with a low prevalence of pulmonary congestion in patients initiated on dialysis. Appropriate VDRA administration may prevent pulmonary congestion.",
author = "Shinichi Sueta and Kunio Morozumi and Asami Takeda and Keiji Horike and Yasuhiro Otsuka and Hibiki Shinjo and Minako Murata and Yuki Kato and Kazunori Goto and Daijo Inaguma",
year = "2015",
month = "6",
day = "17",
doi = "10.1007/s10157-014-0994-x",
language = "English",
volume = "19",
pages = "371--378",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "3",

}

Sueta, S, Morozumi, K, Takeda, A, Horike, K, Otsuka, Y, Shinjo, H, Murata, M, Kato, Y, Goto, K & Inaguma, D 2015, 'Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease', Clinical and Experimental Nephrology, vol. 19, no. 3, pp. 371-378. https://doi.org/10.1007/s10157-014-0994-x

Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease. / Sueta, Shinichi; Morozumi, Kunio; Takeda, Asami; Horike, Keiji; Otsuka, Yasuhiro; Shinjo, Hibiki; Murata, Minako; Kato, Yuki; Goto, Kazunori; Inaguma, Daijo.

In: Clinical and Experimental Nephrology, Vol. 19, No. 3, 17.06.2015, p. 371-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease

AU - Sueta, Shinichi

AU - Morozumi, Kunio

AU - Takeda, Asami

AU - Horike, Keiji

AU - Otsuka, Yasuhiro

AU - Shinjo, Hibiki

AU - Murata, Minako

AU - Kato, Yuki

AU - Goto, Kazunori

AU - Inaguma, Daijo

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Background: Vitamin D deficiency is common among patients with chronic kidney disease (CKD). However, the benefits of vitamin D supplementation versus vitamin D receptor activator (VDRA) administration have yet to be established. Recently, an association between activated vitamin D and cardiovascular factors was reported. To evaluate the benefits of VDRA in advanced CKD, we analyzed the association between VDRA administration and the prevalence of pulmonary congestion. Methods: This retrospective, cross-sectional analysis included patients initiated on dialysis between October 2011 and September 2013 at 17 Japanese institutions. Data from 952 participants were analyzed using a multivariate logistic regression model and a linear regression model. We also analyzed subgroup data for groups classified by selection of peritoneal dialysis or hemodialysis. Results: Of the 952 participants, 303 patients received VDRA. VDRA administration was associated with a low prevalence of pulmonary congestion in the multivariate logistic regression model (odds ratio [OR], 0.64; 95 % confidence interval [CI], 0.44–0.94; P = 0.02). There was no significant association between VDRA administration and systolic blood pressure, diastolic blood pressure, or pulse pressure. Subgroup analysis revealed a tendency that VDRA administration was associated with low prevalence of pulmonary congestion in both groups. Conclusions: In this study, VDRA administration was associated with a low prevalence of pulmonary congestion in patients initiated on dialysis. Appropriate VDRA administration may prevent pulmonary congestion.

AB - Background: Vitamin D deficiency is common among patients with chronic kidney disease (CKD). However, the benefits of vitamin D supplementation versus vitamin D receptor activator (VDRA) administration have yet to be established. Recently, an association between activated vitamin D and cardiovascular factors was reported. To evaluate the benefits of VDRA in advanced CKD, we analyzed the association between VDRA administration and the prevalence of pulmonary congestion. Methods: This retrospective, cross-sectional analysis included patients initiated on dialysis between October 2011 and September 2013 at 17 Japanese institutions. Data from 952 participants were analyzed using a multivariate logistic regression model and a linear regression model. We also analyzed subgroup data for groups classified by selection of peritoneal dialysis or hemodialysis. Results: Of the 952 participants, 303 patients received VDRA. VDRA administration was associated with a low prevalence of pulmonary congestion in the multivariate logistic regression model (odds ratio [OR], 0.64; 95 % confidence interval [CI], 0.44–0.94; P = 0.02). There was no significant association between VDRA administration and systolic blood pressure, diastolic blood pressure, or pulse pressure. Subgroup analysis revealed a tendency that VDRA administration was associated with low prevalence of pulmonary congestion in both groups. Conclusions: In this study, VDRA administration was associated with a low prevalence of pulmonary congestion in patients initiated on dialysis. Appropriate VDRA administration may prevent pulmonary congestion.

UR - http://www.scopus.com/inward/record.url?scp=84931004607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931004607&partnerID=8YFLogxK

U2 - 10.1007/s10157-014-0994-x

DO - 10.1007/s10157-014-0994-x

M3 - Article

C2 - 24916005

AN - SCOPUS:84931004607

VL - 19

SP - 371

EP - 378

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 3

ER -